{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:12:21Z","timestamp":1790730741817,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,10,29]],"date-time":"2016-10-29T00:00:00Z","timestamp":1477699200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"NUS Pharmacy Final Year Project Grant","award":["C148-000-003-001"],"award-info":[{"award-number":["C148-000-003-001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s00228-016-2151-9","type":"journal-article","created":{"date-parts":[[2016,10,29]],"date-time":"2016-10-29T09:06:05Z","timestamp":1477731965000},"page":"165-174","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["An evaluation of the completeness of drug-drug interaction-related information in package inserts"],"prefix":"10.1007","volume":"73","author":[{"given":"Giok Qin","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant Edward","family":"Sklar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8712-015X","authenticated-orcid":false,"given":"Hui Ting","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,29]]},"reference":[{"key":"2151_CR1","unstructured":"Rowland MTT Clinical pharmacokinetics and pharmacodynamics: concepts and applications. Wolters Kluwer Health\/Lippincott William & Wilkins, Baltimore, MD, Philadelphia, PA"},{"issue":"6","key":"2151_CR2","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/pds.1351","volume":"16","author":"ML Becker","year":"2007","unstructured":"Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH (2007) Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf 16(6):641\u2013651. doi: 10.1002\/pds.1351","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"2151_CR3","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1345\/aph.1A333","volume":"36","author":"PJ McDonnell","year":"2002","unstructured":"McDonnell PJ, Jacobs MR (2002) Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 36(9):1331\u20131336","journal-title":"Ann Pharmacother"},{"issue":"6","key":"2151_CR4","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2165\/00002018-200831060-00007","volume":"31","author":"Y Ko","year":"2008","unstructured":"Ko Y, Malone DC, Skrepnek GH, Armstrong EP, Murphy JE, Abarca J, Rehfeld RA, Reel SJ, Woosley RL (2008) Prescribers\u2019 knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers. Drug Saf 31(6):525\u2013536","journal-title":"Drug Saf"},{"issue":"1","key":"2151_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1197\/jamia.M2224","volume":"14","author":"Y Ko","year":"2007","unstructured":"Ko Y, Abarca J, Malone DC, Dare DC, Geraets D, Houranieh A, Jones WN, Nichol WP, Schepers GP, Wilhardt M (2007) Practitioners\u2019 views on computerized drug-drug interaction alerts in the VA system. J Am Med Inform Assoc 14(1):56\u201364. doi: 10.1197\/jamia.M2224","journal-title":"J Am Med Inform Assoc"},{"issue":"6","key":"2151_CR6","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/intqhc\/mzn038","volume":"20","author":"F Mille","year":"2008","unstructured":"Mille F, Schwartz C, Brion F, Fontan JE, Bourdon O, Degoulet P, Jaulent MC (2008) Analysis of overridden alerts in a drug-drug interaction detection system. Int J Qual Health Care 20(6):400\u2013405. doi: 10.1093\/intqhc\/mzn038","journal-title":"Int J Qual Health Care"},{"issue":"Suppl 1","key":"2151_CR7","doi-asserted-by":"publisher","first-page":"i45","DOI":"10.1136\/amiajnl-2011-000262","volume":"18","author":"AM Miller","year":"2011","unstructured":"Miller AM, Boro MS, Korman NE, Davoren JB (2011) Provider and pharmacist responses to warfarin drug-drug interaction alerts: a study of healthcare downstream of CPOE alerts. J Am Med Inform Assoc 18(Suppl 1):i45\u2013i50. doi: 10.1136\/amiajnl-2011-000262","journal-title":"J Am Med Inform Assoc"},{"issue":"1","key":"2151_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/jamia.2010.007609","volume":"18","author":"KR Saverno","year":"2011","unstructured":"Saverno KR, Hines LE, Warholak TL, Grizzle AJ, Babits L, Clark C, Taylor AM, Malone DC (2011) Ability of pharmacy clinical decision-support software to alert users about clinically important drug-drug interactions. J Am Med Inform Assoc 18(1):32\u201337. doi: 10.1136\/jamia.2010.007609","journal-title":"J Am Med Inform Assoc"},{"issue":"2","key":"2151_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1345\/aph.1L333","volume":"43","author":"PS Wong","year":"2009","unstructured":"Wong PS, Ko Y, Sklar GE (2009) Identification and evaluation of pharmacists\u2019 commonly used drug information sources. Ann Pharmacother 43(2):347\u2013352. doi: 10.1345\/aph.1L333","journal-title":"Ann Pharmacother"},{"key":"2151_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13326-015-0018-0","volume":"6","author":"LB Peters","year":"2015","unstructured":"Peters LB, Bahr N, Bodenreider O (2015) Evaluating drug-drug interaction information in NDF-RT and DrugBank. J Biomed Semantics 6:19. doi: 10.1186\/s13326-015-0018-0","journal-title":"J Biomed Semantics"},{"issue":"6","key":"2151_CR11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1365-2125.2006.02809.x","volume":"63","author":"AI Vitry","year":"2007","unstructured":"Vitry AI (2007) Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol 63(6):709\u2013714. doi: 10.1111\/j.1365-2125.2006.02809.x","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"2151_CR12","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1345\/aph.1L255","volume":"42","author":"CM Wong","year":"2008","unstructured":"Wong CM, Ko Y, Chan A (2008) Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia. Ann Pharmacother 42(12):1737\u20131748. doi: 10.1345\/aph.1L255","journal-title":"Ann Pharmacother"},{"key":"2151_CR13","unstructured":"van Boxtel CJ, Santoso B, Edwards I Ralph (2003) Drug benefits and risks: International Textbook of Clinical Pharmacology. John Wiley & Sons Ltd, Chichester, West Syssex"},{"issue":"21","key":"2151_CR14","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1001\/jama.292.21.2655","volume":"292","author":"JD Piorkowski Jr","year":"2004","unstructured":"Piorkowski JD Jr (2004) Bayer\u2019s response to \u201cpotential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis\u201d. JAMA 292(21):2655\u20132657 . doi: 10.1001\/jama.292.21.2655 discussion 2658-2659","journal-title":"JAMA"},{"issue":"21","key":"2151_CR15","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1001\/jama.292.21.2622","volume":"292","author":"BM Psaty","year":"2004","unstructured":"Psaty BM, Furberg CD, Ray WA, Weiss NS (2004) Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA 292(21):2622\u20132631. doi: 10.1001\/jama.292.21.2622","journal-title":"JAMA"},{"issue":"21","key":"2151_CR16","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","volume":"292","author":"DJ Graham","year":"2004","unstructured":"Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292(21):2585\u20132590. doi: 10.1001\/jama.292.21.2585","journal-title":"JAMA"},{"issue":"1","key":"2151_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2125.1998.00050.x","volume":"46","author":"RB Diasio","year":"1998","unstructured":"Diasio RB (1998) Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase. Br J Clin Pharmacol 46(1):1\u20134","journal-title":"Br J Clin Pharmacol"},{"key":"2151_CR18","unstructured":"Welfare MoHa (1997) Guidelines for package inserts for prescription drugs, notification no. 606 of Pharmaceutical Affairs Bureau. In: Welfare TMoHa (ed)"},{"key":"2151_CR19","unstructured":"Welfare MoHa (1997) Guidelines for package inserts for prescription drugs, notification no. 59 of the safety division, Pharmaceutical Affairs Bureau. In: Welfare TMoHa (ed)"},{"key":"2151_CR20","unstructured":"Welfare MoHa (1997) Ministry of Health and Welfare (1997) Guidelines for precautions for prescription drugs, notification no. 607 of Pharmaceutical Affairs Bureau. In: Welfare TMoHa (ed)"},{"key":"2151_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/dhps.s29402","volume":"4","author":"SA Al-Aqeel","year":"2012","unstructured":"Al-Aqeel SA (2012) Evaluation of medication package inserts in Saudi Arabia. Drug Healthc Patient Saf 4:33\u201338. doi: 10.2147\/dhps.s29402","journal-title":"Drug Healthc Patient Saf"},{"issue":"3","key":"2151_CR22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.4314\/tjpr.v12i3.25","volume":"12","author":"K Diobi","year":"2013","unstructured":"Diobi K, Fakeye TO, Adisa R (2013) Community pharmacists\u2019 perception of the relevance of drug package insert as source of drug information in southwestern Nigeria. Trop J Pharm Res 12(3):439\u2013443. doi: 10.4314\/tjpr.v12i3.25","journal-title":"Trop J Pharm Res"},{"issue":"2","key":"2151_CR23","first-page":"322","volume":"4","author":"iN Solanki","year":"2015","unstructured":"Solanki iN, Chhaiya SB, Mehta DS, Trivedi M, Acharya T, Patel D (2015) Analytical evaluation of drug package inserts in India. Int J Basic Clin Pharmacol 4(2):322\u2013324","journal-title":"Int J Basic Clin Pharmacol"},{"issue":"5\u20136","key":"2151_CR24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00228-005-0943-4","volume":"61","author":"V Bergk","year":"2005","unstructured":"Bergk V, Haefeli WE, Gasse C, Brenner H, Martin-Facklam M (2005) Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature. Eur J Clin Pharmacol 61(5\u20136):327\u2013335. doi: 10.1007\/s00228-005-0943-4","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"2151_CR25","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00228-005-0974-x","volume":"61","author":"M Saito","year":"2005","unstructured":"Saito M, Hirata-Koizumi M, Miyake S, Hasegawa R (2005) Comparison of information on the pharmacokinetic interactions of Ca antagonists in the package inserts from three countries (Japan, USA and UK). Eur J Clin Pharmacol 61(7):531\u2013536. doi: 10.1007\/s00228-005-0974-x","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"2151_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1365-2710.2004.00605.x","volume":"30","author":"M Saito","year":"2005","unstructured":"Saito M, Hirata-Koizumi M, Urano T, Miyake S, Hasegawa R (2005) A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. J Clin Pharm Ther 30(1):21\u201337. doi: 10.1111\/j.1365-2710.2004.00605.x","journal-title":"J Clin Pharm Ther"},{"key":"2151_CR27","unstructured":"U.S. Department of Health and Human Services FDA, Center for Drug Evaluation and Research (CDER) (2012) Guidance for industry drug interaction studies\u2014study design, data analysis, implications for dosing, and labeling recommendations In: ed., p 58\u201362"},{"issue":"10","key":"2151_CR28","doi-asserted-by":"publisher","first-page":"e46234","DOI":"10.1371\/journal.pone.0046234","volume":"7","author":"MF Contarino","year":"2012","unstructured":"Contarino MF, Groot PF, van der Meer JN, Bour LJ, Speelman JD, Nederveen AJ, van den Munckhof P, Tijssen MA, Schuurman PR, van Rootselaar AF (2012) Is there a role for combined EMG-fMRI in exploring the pathophysiology of essential tremor and improving functional neurosurgery? PLoS One 7(10):e46234. doi: 10.1371\/journal.pone.0046234","journal-title":"PLoS One"},{"issue":"5","key":"2151_CR29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2165\/00003088-199835050-00003","volume":"35","author":"JH Lin","year":"1998","unstructured":"Lin JH, Lu AY (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35(5):361\u2013390. doi: 10.2165\/00003088-199835050-00003","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"2151_CR30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.18553\/jmcp.2003.9.6.513","volume":"9","author":"CC Peng","year":"2003","unstructured":"Peng CC, Glassman PA, Marks IR, Fowler C, Castiglione B, Good CB (2003) Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population. J Manag Care Pharm 9(6):513\u2013522","journal-title":"J Manag Care Pharm"},{"issue":"12","key":"2151_CR31","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1073\/pnas.1216150110","volume":"110","author":"F Cotel","year":"2013","unstructured":"Cotel F, Exley R, Cragg SJ, Perrier J-F (2013) Serotonin spillover onto the axon initial segment of motoneurons induces central fatigue by inhibiting action potential initiation. Proc Natl Acad Sci 110(12):4774\u20134779. doi: 10.1073\/pnas.1216150110","journal-title":"Proc Natl Acad Sci"},{"key":"2151_CR32","unstructured":"Novartis Pharma Lescol (fluvastatin) (2012). Package insert. Basel, Switzerland ,CH. Available from: http:\/\/eservice.hsa.gov.sg\/prism\/common\/enquirepublic\/SearchDRBProduct.do?action=load . Accessed 10 Aug 2015"},{"key":"2151_CR33","unstructured":"MSD Pharma. Zocor (simvastatin) (2014). package insert. Singapore, SG. Available from: http:\/\/eservice.hsa.gov.sg\/prism\/common\/enquirepublic\/SearchDRBProduct.do?action=load . Accessed 10 Aug 2015"},{"key":"2151_CR34","unstructured":"Pfizer. Lipitor (atorvastatin) (2014). Package insert. New York, US. Available from: http:\/\/eservice.hsa.gov.sg\/prism\/common\/enquirepublic\/SearchDRBProduct.do?action=load . Accessed 10 Aug 2015"},{"key":"2151_CR35","unstructured":"AstraZeneca UK Ltd. Crestor (rosuvastatin) (2015). Package insert. Macclesfield, Cheshire ,UK. Available from: http:\/\/eservice.hsa.gov.sg\/prism\/common\/enquirepublic\/SearchDRBProduct.do?action=load . Accessed 10 Aug 2015"},{"key":"2151_CR36","unstructured":"Sanofi aventis. Ketek (telithromycin) (2006). Package insert. Italy, IT. Available from: http:\/\/eservice.hsa.gov.sg\/prism\/common\/enquirepublic\/SearchDRBProduct.do?action=load . Accessed 10 Aug 2015"},{"key":"2151_CR37","unstructured":"Abbott. Klacid (clarithromycin) (2014). Package insert. United States, US. Available from: http:\/\/eservice.hsa.gov.sg\/prism\/common\/enquirepublic\/SearchDRBProduct.do?action=load . Accessed 10 Aug 2015."},{"key":"2151_CR38","unstructured":"Pfizer. Zithromax (azithromycin) (2015). Package insert. New York, US. Available from: http:\/\/eservice.hsa.gov.sg\/prism\/common\/enquirepublic\/SearchDRBProduct.do?action=load . Accessed 10 Aug 2015"},{"key":"2151_CR39","unstructured":"Merck & Co. Crixivan (indinavir) (2012). Package insert. New Jersey, US. Available from: http:\/\/eservice.hsa.gov.sg\/prism\/common\/enquirepublic\/SearchDRBProduct.do?action=load . Accessed 1 Nov 2015"},{"key":"2151_CR40","unstructured":"Bristol-Myers Squibb. Reyataz (atazanavir) (2014). Package insert. Indiana, US. Available from: http:\/\/eservice.hsa.gov.sg\/prism\/common\/enquirepublic\/SearchDRBProduct.do?action=load . Accessed 1 Nov 2015"},{"key":"2151_CR41","unstructured":"Johnson & Johnson. Prezista (darunavir) (2014). Package insert. Singapore, SG. Available from: http:\/\/eservice.hsa.gov.sg\/prism\/common\/enquirepublic\/SearchDRBProduct.do?action=load . Accessed 1 Nov 2015\u00a0"},{"key":"2151_CR42","unstructured":"Aesica Queenborough. Norvir (ritonavir) (2014). Package insert. Florida,US. Available from: http:\/\/eservice.hsa.gov.sg\/prism\/common\/enquirepublic\/SearchDRBProduct.do?action=load . Accessed 1 Nov 2015"},{"key":"2151_CR43","unstructured":"MSD. Victrelis (boceprevir) (2014). Package insert. Singapore, SG. Available from: http:\/\/eservice.hsa.gov.sg\/prism\/common\/enquirepublic\/SearchDRBProduct.do?action=load . Accessed 1 Nov 2015"},{"key":"2151_CR44","unstructured":"AbbVie. Kaletra (lopinavir\/ritonavir) (2015). Package insert. North Chicago, US. Available from: http:\/\/eservice.hsa.gov.sg\/prism\/common\/enquirepublic\/SearchDRBProduct.do?action=load . Accessed 1 Nov 2015"},{"key":"2151_CR45","unstructured":"Bristol-Myers Squibb. Sunvepra (asunaprevir) (2015). Package insert. Singapore, SG. Available from: http:\/\/eservice.hsa.gov.sg\/prism\/common\/enquirepublic\/SearchDRBProduct.do?action=load . Accessed 1 Nov 2015"},{"key":"2151_CR46","unstructured":"Bristol-Myers Squibb. Taxol (paclitaxel) (2013). Package insert. Sermoneta, Latina, IT. Available from: http:\/\/eservice.hsa.gov.sg\/prism\/common\/enquirepublic\/SearchDRBProduct.do?action=load . Accessed 1 Nov 2015"},{"key":"2151_CR47","unstructured":"AmdiPharma. Cafergot (ergotamine) (2013). Package insert. Ireland, IE. Available from: http:\/\/eservice.hsa.gov.sg\/prism\/common\/enquirepublic\/SearchDRBProduct.do?action=load . Accessed 1 Nov 2015"},{"key":"2151_CR48","unstructured":"GlaxoSmithKline. Marevan (warfarin) (2014). Package insert. Available from: http:\/\/eservice.hsa.gov.sg\/prism\/common\/enquirepublic\/SearchDRBProduct.do?action=load . Accessed 1 Nov 2015"},{"key":"2151_CR49","unstructured":"Novartis Pharma. Sandimmun Neoral (ciclosporin) (2014). Package insert. Basel, CH. Available from: http:\/\/eservice.hsa.gov.sg\/prism\/common\/enquirepublic\/SearchDRBProduct.do?action=load . Accessed 1 Nov 2015"},{"key":"2151_CR50","unstructured":"Astellas Pharma. Advagraf (tacrolimus) (2014). Package insert. Killorglin, Co. Kerry, IE. Available from: http:\/\/eservice.hsa.gov.sg\/prism\/common\/enquirepublic\/SearchDRBProduct.do?action=load . Accessed 1 Nov 2015"},{"key":"2151_CR51","unstructured":"Pfizer. Rapamune (sirolimus) (2015). Package insert. Singapore, SG. Available from: http:\/\/eservice.hsa.gov.sg\/prism\/common\/enquirepublic\/SearchDRBProduct.do?action=load . Accessed 1 Nov 2015"},{"key":"2151_CR52","unstructured":"Pfizer. Dilantin (phenytoin) (2015). Package insert. New York ,US. Available from: http:\/\/eservice.hsa.gov.sg\/prism\/common\/enquirepublic\/SearchDRBProduct.do?action=load . Accessed 1 Nov 2015"},{"issue":"3","key":"2151_CR53","doi-asserted-by":"crossref","first-page":"266","DOI":"10.18433\/J35C7Z","volume":"12","author":"CS Moura","year":"2009","unstructured":"Moura CS, Acurcio FA, Belo NO (2009) Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci 12(3):266\u2013272","journal-title":"J Pharm Pharm Sci"},{"issue":"1","key":"2151_CR54","doi-asserted-by":"publisher","first-page":"104 e101","DOI":"10.1016\/j.jcrc.2010.04.014","volume":"26","author":"A Rivkin","year":"2011","unstructured":"Rivkin A, Yin H (2011) Evaluation of the role of the critical care pharmacist in identifying and avoiding or minimizing significant drug-drug interactions in medical intensive care patients. J Crit Care 26(1):104 e101\u2013104 e106. doi: 10.1016\/j.jcrc.2010.04.014","journal-title":"J Crit Care"},{"issue":"8","key":"2151_CR55","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00228-004-0812-6","volume":"60","author":"V Bergk","year":"2004","unstructured":"Bergk V, Gasse C, Schnell R, Haefeli WE (2004) Requirements for a successful implementation of drug interaction information systems in general practice: results of a questionnaire survey in Germany. Eur J Clin Pharmacol 60(8):595\u2013602. doi: 10.1007\/s00228-004-0812-6","journal-title":"Eur J Clin Pharmacol"},{"key":"2151_CR56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/HSI.S3679","volume":"3","author":"KY-L Yap","year":"2010","unstructured":"Yap KY-L, Chan A, Chui WK (2010) Opinions on drug interaction sources in anticancer treatments and parameters for an oncology-specific database by pharmacy practitioners in Asia. Health Services Insights 3:1","journal-title":"Health Services Insights"},{"issue":"2","key":"2151_CR57","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1001\/jama.2015.7515","volume":"314","author":"A Pursnani","year":"2015","unstructured":"Pursnani A, Massaro JM, D\u2019Agostino RB Sr, O\u2019Donnell CJ, Hoffmann U (2015) Guideline-based statin eligibility, coronary artery calcification, and cardiovascular events. JAMA 314(2):134\u2013141. doi: 10.1001\/jama.2015.7515","journal-title":"JAMA"},{"issue":"25 Pt B","key":"2151_CR58","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW (2014) 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines. J Am Coll Cardiol 63(25 Pt B):2889\u20132934. doi: 10.1016\/j.jacc.2013.11.002","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"2151_CR59","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1056\/nejm199803263381301","volume":"338","author":"FJ Palella Jr","year":"1998","unstructured":"Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 338(13):853\u2013860. doi: 10.1056\/nejm199803263381301","journal-title":"N Engl J Med"},{"issue":"3","key":"2151_CR60","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.pec.2007.11.018","volume":"70","author":"AI Charvet-Berard","year":"2008","unstructured":"Charvet-Berard AI, Chopard P, Perneger TV (2008) Measuring quality of patient information documents with an expanded EQIP scale. Patient Educ Couns 70(3):407\u2013411. doi: 10.1016\/j.pec.2007.11.018","journal-title":"Patient Educ Couns"},{"issue":"3","key":"2151_CR61","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0738-3991(01)00225-7","volume":"47","author":"CE Rees","year":"2002","unstructured":"Rees CE, Ford JE, Sheard CE (2002) Evaluating the reliability of DISCERN: a tool for assessing the quality of written patient information on treatment choices. Patient Educ Couns 47(3):273\u2013275","journal-title":"Patient Educ Couns"},{"issue":"2","key":"2151_CR62","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/intqhc\/mzq004","volume":"22","author":"KY Yap","year":"2010","unstructured":"Yap KY, Raaj S, Chan A (2010) OncoRx-IQ: a tool for quality assessment of online anticancer drug interactions. Int J Qual Health Care 22(2):93\u2013106. doi: 10.1093\/intqhc\/mzq004","journal-title":"Int J Qual Health Care"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2151-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-016-2151-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2151-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T20:03:24Z","timestamp":1657569804000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-016-2151-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,29]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["2151"],"URL":"https:\/\/doi.org\/10.1007\/s00228-016-2151-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,29]]}}}